New and Under-utilized Vaccines Implementation (NUVI)

Decision making and Implementation of Conjugate Hib Vaccines

Surveillance and countries with functional sentinel sites

VP-IBD Surveillance: Tier 2 Meningitis-Sepsis-Pneumonia Surveillance

Percent of Probable Bacterial Meningitis Cases with HI, by Years of Hib Vaccine Introduction & WHO Region, 2009 (regional medians with country-specific ranges)

Percent of suspected meningitis cases with probable bacterial meningitis, by country and WHO Regions, 2009

Tier 1: Meningitis Surveillance Data, 2008 Compared with 2009

Tier 1 VP-IBD Countries: Meningitis Surveillance

Countries in WHO VP-IBD Surveillance Network, by WHO Region and GAVI Eligibility, 2009

IBD Surveillance - Countries participating in the WHO Network and Reporting Data for 2009

Functional sentinel sites

Countries with functional sentinel sites reporting to WHO - 2008

Cases and indicators: Africa

PBM surveillance performance indicators in AFR 2003 - 2006

Total patients with lab samples, H. influenzae , and S. pneumoniae isolated AFR countries with Hib vaccine introduced 2002-2006*

Cases and indicators: Americas

Hib isolates from invasive diseases in children aged < 6 years - Selected AMR countries - 2000-2004

Cases and indicators: Eastern mediterranean

PBM surveillance performance indicators in EMR 2004 - 2006

Total patients with lab samples, H. influenzae , and S. pneumoniae isolated EMR countries with Hib vaccine introduced 2004-2006*

Percent of probable meningitis with HI, Spn or NM identified, by country and WHO region, 2009

IBD Surveillance, Tier 2 Meningitis-Sepsis-Pneumonia - Numbers of reporting countries & children enrolled with pneumonia with % change from 2008 to 2009, by WHO region

Tier 2: Meningitis-Pneumonia-Sepsis Detected Organisms, 2009

Spn. Serotype Data, Tier 1: Meningitis

IBD and Rotavirus Global and Regional Laboratory Network Structure, 2010

Last updated: 17 February 2011

Share
Email Twitter Facebook Google Delicious LinkedIn
More...

Table of contents

  1. Disease Burden
  2. Vaccine Utilization
  3. Surveillance and countries with functional sentinel sites